ライフサイエンスコーパス: sialyl Lewis X

1 egrins or selectin carbohydrate ligands (eg, sialyl-Lewis(x)).

2 provide functional oligosaccharides such as sialyl Lewis(X).

3 receptors that present carbohydrates such as sialyl Lewis(x).

4 -detectable glyconanoparticles conjugated to sialyl Lewis(X).

5 essed normal levels of CD18, L-selectin, and sialyl-Lewis(x).

6 ctable sulfation of GlcNAc in the context of sialyl Lewis x.

7 that comprise structural motifs derived from sialyl Lewis x.

8 lanoma and human lung tumor cells expressing sialyl Lewis X.

9 ent groups based on the expression levels of sialyl Lewis X.

10 lung nodules as B16-FTIII.N cells which lack sialyl Lewis X.

11 various functional oligosaccharides, such as sialyl Lewis X.

12 lfate and GlcNAc-6-sulfate in the context of sialyl Lewis x.

13 d N-acetylglucosamine [GlcNAc]-6-sulfate) of sialyl Lewis x.

14 y 4-fold 3'-sulfo Lewis x, as compared to 3'-sialyl Lewis x.

15 humans through the generation of functional sialyl Lewis X.

16 d in mice, in large part by interacting with sialyl-Lewis X.

17 Several N-acylglucosamine derivatives of sialyl Lewis X (1-3) were prepared using a combined chem

18 Moreover, sialyl Lewis x (17) was synthesized via the enzymatic fu

19 osylated glycan receptors, including 6-sulfo-sialyl Lewis x (6-sulfo-sLe(x)).

20 L-selectin binds to the sulfated sialyl Lewis x (6-sulfo-sLex) epitope present on O-glyca

21 omplex with its prime glycan target 6'-sulfo sialyl Lewis(x) A canonical motif for sialic acid recogn

22 rate structural analysis showed that 6-sulfo sialyl Lewis X, a dominant ligand for L-selectin, was al

23 This epitope overlaps with 6-sulfo sialyl Lewis x, a recognition determinant for L-selectin

24 ro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on

25 pport the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemina

26 ell binding is because of markedly decreased sialyl-Lewis(x/a) (sLe(x/a)) carbohydrate ligand-binding

27 uraminic acid, 5-N-glycolyl neuraminic acid, sialyl-Lewis(X), alpha2,3-sialyl-N-acetyl-lactosamine an

28 Reported herein is the synthesis of sialyl Lewis(X) analogues bearing a trans-bicyclo[4.4.0]

29 tment resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1,

30 eactive with HECA-452, a mAb that recognizes sialyl Lewis X and related structures.

31 The selectin ligand components sialyl Lewis x and sialyl Lewis a are oncodevelopmental

32 ere inhibited, we analyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (C

33 Structural groups such as sialyl Lewis(x) and NeuAc alpha2-3 substituted Galbeta1-

34 nhibitors of selectin binding to immobilized sialyl Lewis(X) and of cell adhesion to immobilized sele

35 introduced glyco-patterns range from common sialyl Lewis(x) and sialyl lacto-chains to chemically fu

36 detect binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X) but not to Lewis(A), Lewis(

37 es the binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X).

38 oll" (via interactions between selectins and sialyl-Lewis-x), and then firmly adhere to the vascular

39 cytometry, bimodal patterns of expression of sialyl-Lewis X- and sialyl-dimeric-Lewis X were observed

40 re colon cancer HT29 cells by using multiple Sialyl Lewis X antibodies (aSlex)-conjugated PAMAM dendr

41 at occur as two major species containing the sialyl Lewis x antigen; one species is a disialylated, m

42 ide but does not bind to GM1, GD1a, GT1b, or sialyl Lewis(X) antigens.

43 relevant branched oligosaccharides, such as sialyl Lewis(x), as well as sulfated glycosaminoglycan-l

44 ugh it has been shown to more effective than sialyl Lewis x at blocking the L-selectin-GlyCAM-1 inter

45 nd CD11b are all required for PMN binding to sialyl Lewis(x)-bearing LS174T cells at high shear (800

46 Resulting reduction in the sialyl Lewis-X-bearing epitopes on this ligand may reduc

47 ts, we propose possible pathways for 6-sulfo sialyl Lewis x biosynthesis and suggest that sulfation m

48 Pre-incubation of SSL11 with the glycan Sialyl Lewis X blocked SSL11 function and de-glycosylati

49 and fucosylated alpha2-3 glycans (including sialyl Lewis x), both of which may be important receptor

50 monosialylated, core 2-based O-glycan with a sialyl Lewis x (C2-O-sLe(x)) motif at a specific Thr res

51 pating in the synthesis of core 2-associated sialyl Lewis x (C2-O-sLe(x)), a ligand involved in selec

52 idue with a core 2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

53 an adjacent core-2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

54 lfates and a Core 2 O-glycan terminated with sialyl Lewis(X) (C2-O-sLe(X)).

55 correlated with their reduced expression of sialyl Lewis x (CD15s), a putative cellular receptor com

56 IgM mAb to Lewis(x) (CD15) and sialyl Lewis(x) (CD15s), which are carbohydrate antigens

57 e developed a cell-free adhesion assay using sialyl Lewis(x)-coated microspheres and E-selection-IgG

58 Sialyl Lewis(x)-coated microspheres attach to and roll o

59 m the neutrophil surface during rolling on a sialyl Lewis x-coated planar surface at physiological sh

60 -selectin on neutrophils during rolling on a sialyl Lewis x-coated surface that involves mechanical f

61 on both E- and P-selectin and suggest that a sialyl Lewis x-containing glycan at Threonine-16 is crit

62 We tested this hypothesis using sialyl Lewis X-dependent B16 melanoma lung targeting and

63 n the lung vasculature plays a major role in sialyl Lewis X-dependent cancer cells targeting to the l

64 ational analysis with NMR indicated that the sialyl Lewis x domain of 1 retained the conformation of

65 Results demonstrate that 1) the sLe(X) (sialyl-Lewis-X) epitope is expressed in P-selectin glyco

66 and glycosphingolipid structures displaying sialyl Lewis X epitopes as potential E-selectin ligands

67 deep within corpus glands in vivo only when sialyl-Lewis X expanded during SPEM.

68 n E/P-selectin doubly deficient mutant mice, sialyl Lewis X-expressing B16 melanoma cells colonized t

69 carbohydrate-dependent lung colonization of sialyl Lewis X-expressing B16-FTIII-M cells in E/P-selec

70 ranose) action by contrasting the effects on sialyl Lewis X expression displayed by P-selectin glycop

71 inhibitor to reduce O-linked glycosylation, sialyl Lewis-X formation, and leukocyte adhesion via the

72 e selectins were blocked with an analogue of sialyl-Lewis(x) given as an I.V. bolus of 10 mg/kg follo

73 The sialyl Lewis(X) glycomimetic featuring this rigidified b

74 of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLex) to inhibit comple

75 Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sC

76 It has been established that sialyl Lewis x in core 2 branched O-glycans serves as an

77 tes, although less than CHO cells expressing sialyl Lewis x in core 2 branched O-glycans.

78 nsfected cells carried comparable amounts of sialyl Lewis x in extended core 1 and core 2 branched O-

79 These results indicate that sialyl Lewis x in extended core 1 O-glycans can function

80 In a rolling assay, CHO cells expressing sialyl Lewis x in extended core 1 O-glycans supported a

81 To determine the roles of sialyl Lewis x in extended core 1 O-glycans, Chinese ham

82 critical function of N-glycan-linked 6-sulfo sialyl Lewis X in L-selectin-dependent lymphocyte homing

83 FTIII.M cells expressing moderate amounts of sialyl Lewis X in poly-N-acetyllactosamines produced lar

84 III.H cells expressing the highest amount of sialyl Lewis X in shorter N-glycans died in lung blood v

85 esults indicate that excessive expression of sialyl Lewis X in tumor cells leads to rejection by NK c

86 In order to determine the roles of sialyl Lewis X in tumor metastasis, mouse melanoma B16-F

87 ysis confirmed the expression of Lewis X and sialyl-Lewis X in the intracellular granules and on the

88 Sulfation of GlcNAc within sialyl Lewis x is a crucial modification for L-selectin

89 ession of cell surface carbohydrates such as sialyl Lewis X is associated with tumor formation and me

90 Our results show that sialyl Lewis(x) is a minimal functional recognition elem

91 ied a class of N-glycans bearing the 6-sulfo sialyl Lewis X L-selectin ligand in high endothelial ven

92 egulation of endothelial selectins that bind sialyl Lewis(x) ligands and activation of beta(2)-integr

93 In contrast, sialyl Lewis(x)-low HCT-8 cells fail to aggregate with P

94 Furthermore, saliva/sialyl Lewis(X) mediated signaling enhanced intracellula

95 mmunoprecipitated from ccRCC tissue contains sialyl Lewis X moieties (the ligand recognized by E-sele

96 Sialyl Lewis X moieties are critical for ligand activity

97 at adding fucose to human Tregs, forming the Sialyl Lewis X moiety on P-selectin glycoprotein ligand-

98 eu5Acalpha2-3Galbeta1-4GlcNAc, including the sialyl-Lewis(x) motif and structures containing 6-sulfog

99 de 1) diminishes the formation of the glycan sialyl Lewis X (Neu5Acalpha2-3Galbeta1-4(Fucalpha1-3) Gl

100 ied by the emergence of the CSLEX-1 epitope, sialyl Lewis x (NeuAcalpha2,3Galbeta1,4(Fucalpha1,3)GlcN

101 t adhesion on SEC apoptosis was tested using sialyl Lewis-X oligosaccharide (sLe(x)), a natural ligan

102 d SIGNR7 binds preferentially to the 6-sulfo-sialyl Lewis(x) oligosaccharide, whereas SIGNR2 binds al

103 volving the binding of P- and L-selectins to sialyl Lewis(X) oligosaccharide-containing ligands.

104 to recognize both nonsulfated and 6-sulfated sialyl Lewis X on core 2 branched O-glycans, and MECA-79

105 AcT) enabled the construction of the 6-sulfo sialyl Lewis x on extended core1 O-glycans, recapitulati

106 phocytes and the carbohydrate ligand 6-sulfo sialyl Lewis X on high endothelial venules.

107 for a sulfated-glycan binding site (6-sulfo-sialyl Lewis x) on peripheral node addressin.

108 Here we show that binding of E-selectin to sialyl Lewis(x) on L-selectin and PSGL-1 drives their co

109 T, that directs the synthesis of the 6-sulfo sialyl Lewis(x) on L-selectin counterreceptors CD34, Gly

110 sulfated carbohydrate structures (6-sulfated sialyl Lewis x or 6-sulfo-sLex) as a recognition determi

111 g the same sequence inhibited the binding of sialyl Lewis X or sialyl Lewis A oligosaccharides to E-s

112 E-selectin glycoprotein ligand(s); distinct sialyl Lewis X (or HECA-452 antigen)-bearing membrane pr

113 intracellular signals elicited by binding of sialyl Lewis(X) present on salival mucins to l-selectin

114 test the hypothesis that plasma C1INH bears sialyl Lewis(x)-related moieties and therefore binds to

115 demonstrated that plasma C1INH does express sialyl Lewis(x)-related moieties on its N-glycan as dete

116 bind tightly to sugar moieties Lewis(B) and sialyl-Lewis(X), respectively, on the surface of epithel

117 ass spectrometric analyses revealed that the sialyl-Lewis(x) sequence [NeuAcalpha2-3Galbeta1-4(Fucalp

118 Thus, the sialyl-Lewis(x) sequence represents the major carbohydra

119 inhibited by glycoconjugates terminated with sialyl-Lewis(x) sequences or by antibodies directed agai

120 ual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3]

121 ell line, HT-29LMM, expressed high levels of sialyl Lewis x, sialyl Lewis a, alpha(1,3/1,4)fucosyltra

122 the canonical E-selectin binding determinant sialyl Lewis X (sLe(X)) and display markedly greater adh

123 A. phagocytophilum binding to sialyl Lewis x (sLe(x)) and other sialylated glycans tha

124 emarkably, an increment of host-cell-surface sialyl Lewis X (sLe(X)) exacerbates the killing by sever

125 s based on the monomeric carbohydrate ligand sialyl Lewis X (SLe(X)) have low affinities and are not

126 A sialyl Lewis X (sLe(x)) mimetic compound, 2-(trimethylsi

127 ligand sulfotransferase (LSST) forms 6-sulfo sialyl Lewis x (sLe(x)) on both core 2 branch and MECA-7

128 Sialyl Lewis X (sLe(X)) on prostate cancer (PCa) cells i

129 Clustered presentation of sialyl Lewis X (sLe(X)) on tumor cell mucins is thought

130 lpha1-3-fucosylated selectin ligands such as sialyl Lewis x (sLe(x)), although monoclonal antibodies

131 ty by ablating N-acetyllactosamine (LacNAc), sialyl Lewis X (sLe(X)), and related lectin ligands on e

132 hesion proteins P- and L-selectin binding to sialyl Lewis X (sLe(X))-containing ligands, and the myos

133 an intragranulocytic bacterium that utilizes sialyl Lewis x (sLe(x))-modified P-selectin glycoprotein

134 osylated to form glycan determinants such as sialyl Lewis x (sLe(x)).

135 in E-selectin (CD62E) to its cognate ligand, sialyl Lewis-X (sLe (X) ), displayed on circulating cell

136 binding of simple oligosaccharides based on sialyl Lewis-X (sLe(X)) and complex molecules with the c

137 amine structure (Galbeta1,4GlcNAc) to create sialyl Lewis-X (sLe(X)) and related sialofucosylated gly

138 nalysis demonstrate the presence of both the sialyl Lewis-X (sLe(X)) and the di-sialylated T-antigen

139 rks that participate in the formation of the sialyl Lewis-X (sLe(X)) epitope on O-glycans linked to a

140 r conventional Hbonds in the pentasaccharide sialyl Lewis-X (sLe(X)-5) between 5 and 37 degrees C in

141 Core 2 O-glycans terminated with sialyl-Lewis x (sLe(X)) are functionally important oligo

142 Sialyl-Lewis X (sLe(X)) is a tetrasaccharide that serves

143 -sialylated- and alpha1,3-fucosylated-moiety sialyl-Lewis x (sLe(x)), which modifies the PSGL-1 N ter

144 ctin, is capped with sulfated derivatives of sialyl Lewis x [sLe(x): Sia alpha 2-->3Gal beta 1-->4(Fu

145 n of fucosylated alpha2,3 sialoglycan (i.e., sialyl Lewis X [SLe(X)]) in chickens and five common dab

146 The tetrasaccharide sialyl Lewis(x) (sLe(x)) 1 is a ligand for E-, P-, and L

147 Sialyl Lewis(x) (sLe(x)) and Lewis(x) (Le(x)) are known

148 Monomeric sialyl Lewis(X) (sLe(x)) and sLe(x)-like oligosaccharide

149 have reported that microspheres coated with sialyl Lewis(x) (sLe(x)) interact specifically and roll

150 -terminus of PSGL-1 through recognition of a sialyl Lewis(x) (SLe(x)) moiety linked to a properly pos

151 Binding of the P-, L-, and E-selectins to sialyl Lewis(x) (sLe(x)) retards circulating leukocytes,

152 nanometer-scale polymer construct containing sialyl Lewis(x) (sLe(x)) that is found on the surface of

153 f L-selectin and the minimal selectin ligand sialyl Lewis(x) (sLe(x)) to interact with postcapillary

154 res functionalized with the selectin ligand, sialyl Lewis(X) (sLe(X)), and an antibody against ICAM-1

155 find that beads coated with the saccharides sialyl Lewis(x) (sLe(x)), sialyl Lewis(a) (sLe(a)), and

156 ds are glycosylated with the tetrasaccharide sialyl Lewis(x) (sLe(x)), which contributes to bond affi

157 However, the only millimolar affinity of sialyl Lewis(x) (sLe(x)), which is the common tetrasacch

158 ted in a cell-free system; it was shown that sialyl Lewis(x) (sLe(x))-coated microspheres roll over E

159 ed for the ability to inhibit the binding of sialyl Lewis(x) (sLe(x), 2) bearing HL-60 cells to E-, P

160 The oligosaccharide sialyl-Lewis(x) (SLe(x)) is the probable neutrophil coun

161 (AFM) with cantilevers biofunctionalized by sialyl-Lewis(x) (sLe(x)) were employed to investigate Ab

162 s and displays copies of the tetrasaccharide sialyl-Lewis(x) (sLe(X)), as well as a cluster of three

163 the sialylated, fucosylated tetrasaccharide sialyl Lewis X (sLex) is an important component of leuko

164 Sialyl Lewis X (sLex) mimetics that can function as sele

165 Functional PSGL-1 is known to bear sialyl lewis X (SLex) or a closely related oligosacchari

166 In contrast, FUT3, which contributes to sialyl Lewis X (sLeX) production, is preferentially expr

167 Sialyl Lewis X (sLeX) regulates T cell trafficking from

168 igand-1 (PSGL-1), which displays appropriate sialyl Lewis x (sLex)-like carbohydrate determinants for

169 -VII correlated with a subset of mAb-defined sialyl Lewis X (sLex)-like structures.

170 lly important fucoglycoconjugates, including sialyl Lewis x (SLex).

171 erases that construct the glycan determinant sialyl Lewis x (sLex).

172 marker for pancreatic cancer, and its isomer sialyl-Lewis x (SLex, CD15s), which is overexpressed in

173 -selectin glycoprotein ligand-1 [PSGL-1] and Sialyl-Lewis(x) [SLeX]) to rapidly target inflamed tissu

174 alpha1, 3-fucosyltransferase III to express sialyl Lewis X structures.

175 This binding requires the sialyl Lewis x sugar moiety to be placed on both O- and

176 ctivity include a sulfated derivative of the sialyl Lewis x tetrasaccharide.

177 -60 cells and serum albumin derivatized with sialyl-Lewis X tetrasaccharide, thus mimicking the prope

178 We have shown that C1INH expresses the sialyl-Lewis(x) tetrasaccharide on its N-linked glycan,

179 n of HL-60 and B16 melanoma cells expressing sialyl Lewis X to E-selectin was also inhibited by the p

180 ied NK-92MI cells with the E-selectin ligand sialyl Lewis X to promote trafficking to bone marrow.

181 ger than that for integrin binding to RGD or sialyl Lewis(x) to E-selectin.

182 utant mice, whereas the amount of unsulfated sialyl Lewis X was much greater.

183 The selectin ligand sialyl Lewis(x) was conjugated to the microbubble surfac

184 -long glass fibers, and the selectin ligand, sialyl Lewis(x), was coupled to latex microspheres.

185 kingly, bonds between L-selectin and 6-sulfo-sialyl Lewis X were impervious to ramp rate changes.

186 ion to unique carbohydrate ligands, sulfated sialyl Lewis(x), which are expressed on high endothelial

187 rough interaction of its adhesin, SabA, with sialyl-Lewis X, which expanded in SPEM.